Rongchang Biotech announced that the company signed a “license agreement” with the related party Rongchang Pharmaceutical and was granted the right to monopolize, irrevocable, and multi-level sub-licenses for pan-RAS small molecule inhibitors and their products, and can carry out R&D, production, and commercialization activities. The company is required to pay a down payment of 50 million yuan, a maximum milestone payment of 4.870 billion yuan, and royalties based on 3%-7% of annual net sales. This transaction constitutes a related transaction and does not constitute a major asset restructuring. It has been reviewed and approved by the company's board of directors, and still needs to be submitted to the shareholders' meeting for consideration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.